公开(公告)号：US12230378B2

公开(公告)日：2025-02-18

申请号：US17357360

申请日：2021-06-24

Applicant: Iovance Biotherapeutics, Inc.

Inventor： Anne Brooks ,  Steve Macrides ,  Kristin Lanzi

IPC: G16H20/00 ,  A61K35/13 ,  A61K39/00 ,  C12N5/0783 ,  C12N5/09 ,  G06Q10/0832 ,  G16H10/60 ,  G16H80/00

Abstract: A method for coordinating the manufacturing of an expanded cell therapy product for a patient may include receiving a cell order request to expand the cell therapy product for the patient; generating a patient-specific identifier or cell order identifier associated with the cell order request; and initiating a process to expand the cell therapy product from at least some of a solid tumor obtained from the patient. If acceptance parameters for the expansion cell therapy product do not meet certain acceptance criteria at a second time point subsequent to a first time point in the expansion process, it is determined whether re-performing the expansion of the cell therapy product using the cell expansion technique is possible from the first time point based on the acceptance parameters at the second time point. If such re-performing the expansion is possible, patient treatment events that use the expanded cell therapy product are rescheduled.

公开(公告)号：US12186342B2

公开(公告)日：2025-01-07

申请号：US16335653

申请日：2017-09-25

Applicant: The Regents of the University of California

Inventor： Karin Gaensler

IPC: A61K35/13 ,  A61K35/15 ,  A61K38/20 ,  A61K39/00 ,  A61P35/02 ,  C12N5/09 ,  C12N5/10 ,  C12N13/00

Abstract: Provided herein, inter alia, are cell media compositions and whole cell vaccines comprising recombinant cells expressing IL-15, IL-15Rα, and CD80 capable of treating and preventing relapse in individuals diagnosed with or thought to have leukemia as well as methods for using the same.

公开(公告)号：US12016973B2

公开(公告)日：2024-06-25

申请号：US16339674

申请日：2017-10-05

Applicant: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA

Inventor： Klearchos K. Papas

IPC: A61L27/54 ,  A61F2/02 ,  A61K35/12 ,  A61K35/13 ,  A61K38/19 ,  A61K39/39 ,  A61L27/36 ,  A61P35/00 ,  A61K9/00 ,  A61K39/00

CPC classification number: A61L27/54 ,  A61F2/022 ,  A61K35/12 ,  A61K35/13 ,  A61K38/19 ,  A61K39/39 ,  A61L27/3683 ,  A61P35/00 ,  A61K9/0024 ,  A61K2039/515

Abstract: Methods, systems, and devices for enhancing cancer immunotherapy featuring co-transplantation of encapsulated xenogeneic cells with separately encapsulated autologous or allogeneic cells, e.g., autologous or allogeneic tumor cells. For example, both a first cellular transplantation device housing a patient's own tumor cells and a second cellular transplantation device housing xenogeneic cells may be implanted into a patient. The presence of the xenogeneic cells elicits an enhanced immune response, e.g., the xenogeneic cells will draw in a large number of immune cells. Shed tumor antigens from the first cellular transplantation may then be taken up by the immune cells that were drawn to the xenogeneic cells. This will generate an anti-tumor immune response that is amplified relative to a response elicited by the encapsulated tumor cells alone.

公开(公告)号：US20230181633A1

公开(公告)日：2023-06-15

申请号：US17427380

申请日：2020-01-31

Applicant: METACLIPSE THERAPEUTICS CORPORATION ,  EMORY UNIVERSITY

Inventor： Periasamy SELVARAJ ,  Luis Enrique MUNOZ ,  Ramireddy BOMMIREDDY ,  Christopher D. PACK ,  Sampath RAMACHANDIRAN

IPC: A61K35/13 ,  A61K31/155 ,  C07K14/71 ,  C07K16/28 ,  A61P35/00

CPC classification number: A61K35/13 ,  A61K31/155 ,  A61P35/00 ,  C07K14/71 ,  C07K16/2818 ,  C07K16/2896

Abstract: Disclosed herein is a method for treating a subject having, or at risk of having, a cancer, comprising administering to the subject a therapeutically effective amount of a tumor membrane vesicle (TMV) and a metformin. In some embodiments, the TMV comprises a B7-1 and/or IL-12 molecule anchored to a lipid membrane (e.g., by a GPI anchor). In some embodiments, the methods can further comprise administering an immune checkpoint inhibitor. The methods are useful for reducing tumor size and metastasis, and in improving anti-tumor immune responses.

公开(公告)号：US20230149456A1

公开(公告)日：2023-05-18

申请号：US17916193

申请日：2021-03-30

Applicant: Rita E. Serda ,  Jimin Guo ,  Achraf Noureddine ,  Stefan A. Franco ,  Henning DeMay ,  UNM RAINFOREST INNOVATIONS

Inventor： Rita E. Serda ,  Jimin Guo ,  Achraf Noureddine ,  Stefan A. Franco ,  Henning DeMay

IPC: A61K35/13 ,  B82Y5/00 ,  A61K35/74 ,  A61K35/76

CPC classification number: A61K35/13 ,  B82Y5/00 ,  A61K35/74 ,  A61K35/76

Abstract: A silicified cell includes a nanoparticle that carries a bioactive agent. The silicified call can be a tumor cell, a bacterial cell, a virus, or a silicifiable compartment or fragment thereof. The silicified cell can optionally include an immunomodulatory moiety that may be carried within pores of the nanoparticle and/or bound to the surface of the nanoparticle. The silicified cell can be used as a prophylactic or therapeutic treatment for treating tumors or bacterial infections.

公开(公告)号：US20230043806A1

公开(公告)日：2023-02-09

申请号：US17434692

申请日：2020-02-28

Applicant: University of Virginia Patent Foundation ,  Wayne State University

Inventor： Archana Thakur ,  Lawrence G. Lum ,  Srividya Yarlagadda

IPC: A61K35/17 ,  A61K35/13 ,  C07K16/28 ,  A61P35/00

Abstract: Methods and compositions for treating cancer in a subject in need thereof. The method includes administering to the subject an effective amount of a composition comprising Tumor-Targeting Effectors (TITE) derived from a culture comprising a bispecific antibody armed activated T cell (BAT) and a cancer cell, to thereby treat cancer in the subject.

公开(公告)号：US20220324971A1

公开(公告)日：2022-10-13

申请号：US17640005

申请日：2020-09-03

Applicant: Akeso Biopharma, Inc

Inventor： Peng Zhang ,  Baiyong Li ,  Yu Xia ,  Zhongmin Wang

IPC: C07K16/28 ,  A61K35/13 ,  A61P35/00

Abstract: Provided are an anti-CD47 monoclonal antibody and a use thereof, secreted by the hybridoma cell line with the deposit number CCTCC NO: C2018135.

公开(公告)号：US20220135952A1

公开(公告)日：2022-05-05

申请号：US17410126

申请日：2021-08-24

Applicant: Koninklijke Nederlandse Akademie Van Wetenschappen

Inventor： Lars Norman Sachs ,  Jarno Drost

IPC: C12N5/095 ,  C12N5/071 ,  A61K35/13 ,  A61K35/42 ,  G01N33/50

Abstract: The invention relates to improved culture methods for expanding epithelial stem cells and obtaining organoids, to culture media involved in said methods, and to uses of said organoids.

公开(公告)号：US20220118452A1

公开(公告)日：2022-04-21

申请号：US17504947

申请日：2021-10-19

Applicant: The Board of Trustees of the Leland Stanford Junior University

Inventor： Utkan Demirci ,  Mehmet Ozgun Ozen ,  Naside Gozde Durmus ,  Rakhi Gupta ,  Sharon Pitteri ,  Fernando Jose Garcia Marques

IPC: B01L3/00 ,  A61K35/13 ,  B03C1/01 ,  B03C1/28

Abstract: An extracellular vesicle-containing sample can be processed using a device for isolating one or more subpopulations of the extracellular vesicles. The extracellular vesicle-containing sample is flowed through a flow chamber of the device under an applied fluid pressure, in which the device has one or more inlets and two or more outlets in fluid communication with one another via the flow chamber. The device has one or more filters in the flow chamber between the inlet(s) and at least one of the outlet(s). The extracellular vesicle-containing sample is flowed through the filter(s) in the flow chamber to sort the extracellular vesicles of extracellular vesicle-containing sample by size into two or more subpopulations of the extracellular vesicles. At least one of the subpopulations that has been sorted flows out of a corresponding one of the outlets. Surface marker-based exosome sorting using magnetic beads may be used after the size-based exosome isolation.

公开(公告)号：US11260076B2

公开(公告)日：2022-03-01

申请号：US15522361

申请日：2015-10-27

Applicant: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.

Inventor： Alicja J. Copik ,  Jeremiah L. Oyer ,  Robert Y. Igarashi ,  Deborah Altomare

IPC: A61K35/17 ,  C12N5/0783 ,  C07K14/54 ,  C07K14/705 ,  C07K14/55 ,  A61K35/13 ,  A61K38/17 ,  A61K38/20 ,  A61K35/12

Abstract: Disclosed herein are novel compositions and methods for stimulation of and the production or expansion of natural killer (NK) cells. Numbers of NK cells can be increased following contact with exosomes modified with one or more stimulatory peptides. Methods and compositions for the production of exosomes, wherein the exosomes comprises stimulatory peptides are also described. Also described are methods of treating cancer using the disclosed NK-stimulating exosomes or NK cells stimulated by the disclosed methods.